Page URL:

Genetic screening provides actionable findings in one in six people

31 August 2021
Appeared in BioNews 1110

Offering healthy people genetic screening could provide clinically important information in over 15 percent of cases.

Researchers from the USA, Canada and Singapore offered proactive screening to adult participants through local primary and specialist healthcare facilities. The samples were screened for variants known or believed to be pathogenic in 147 different genes associated with a range of medical conditions including cancers and cardiovascular disease.

The researchers wrote that their data 'provide a foundation for further studies to assess the role of genetic screening, as part of regular medical care, in reducing morbidity and mortality from actionable genetic disorders and to determine its clinical utility and cost-effectiveness.'

The variants being screened for were all monogenic, actionable variants. An actionable gene is one with consequences that healthcare professionals understand and can act upon. In many cases, knowing that a person has such a variant can help reduce the risk of being affected or the severity of disease through proactive screening, lifestyle changes or medication. 

Almost 10,500 accepted the test, of whom 1619 (15.5 percent) had at least one gene variant conferring increased risk. Of these, 138 people (1.3 percent of the whole group) had two or more such variants. 

Variants associated with cancers were found in 807 participants: genes linked to colorectal cancer were most common, followed by breast and ovarian cancers and melanoma. Six hundred and eight people had variants in genes associated with cardiovascular disease, including heart problems such as arrhythmias and cardiomyopathies, familial hypercholesterolaemia and hereditary thrombophilia. 

Forty-nine participants had variants that put them at risk of serious conditions including hereditary cancers, cardiovascular disorders, or malignant hyperthermia susceptibility. The findings were published in BMC Medicine.

Currently, genetic testing for healthy people is generally limited to the blood spot test for newborns and looking for specific conditions in people where there is a known family history. 

24 January 2022 - by Dr Rachael Boyle 
The NHS has launched a world-first pilot study of predictive genomic testing for the prevention of cardiovascular disease...
22 November 2021 - by BioNews 
A conversation between Sarah Norcross (director of the Progress Educational Trust) and Dr Charles Steward (lead for patient advocacy and engagement at Congenica, and parent of two children with severe neurological disorders)...
22 November 2021 - by Dr Jess Buxton 
A new pilot study embedded in the NHS will explore whether and how to offer whole genome sequencing to newborn babies...
8 November 2021 - by Dr Yvonne Collins 
Currently, only nine conditions are screened for in the UK, which is fewer than many other high-income countries. Although many patient groups advocate for new conditions to be added to the list, this has not happened...
28 June 2021 - by Allison Watson 
Ring chromosome 20 syndrome is an ultra-rare difficult to treat epilepsy, often accompanied by intellectual disability and behaviour disorder...
24 May 2021 - by Dr Hazar Haidar, Professor Vardit Ravitsky and Dr Anne-Marie Laberge 
Non-invasive prenatal testing (NIPT) was first introduced in 2011, when breakthroughs in sequencing technology allowed the analysis of cell-free fetal DNA (cffDNA) in maternal blood to detect genetic abnormalities in the foetus, such as trisomy 21 (Down's syndrome), with greater accuracy than previous screening tests...
17 August 2020 - by Sarah Gregory 
Exome sequencing may not be as reliable as standard blood testing for identifying rare diseases in newborns...
20 July 2020 - by Dr Molly Godfrey 
Screening all women over 30 for the most common breast and ovarian cancer causing mutations could prevent millions of cancer deaths worldwide, according to a new study...
to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions

Syndicate this story - click here to enquire about using this story.